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Background: Transferrin (TF) plays a critical physiological role in cellular iron delivery via the transferrin receptor
(TFR)-mediated endocytosis pathway in nearly all eukaryotic organisms. Human serum TF (hTF) is extensively used
as an iron-delivery vehicle in various mammalian cell cultures for production of therapeutic proteins, and is also
being explored for use as a drug carrier to treat a number of diseases by employing its unique TFR-mediated
endocytosis pathway. With the increasing concerns over the risk of transmission of infectious pathogenic agents of
human plasma-derived TF, recombinant hTF is preferred to use for these applications. Here, we carry out
comparative studies of the TFR binding, TFR-mediated endocytosis and cellular iron delivery of recombinant hTF
from rice (rhTF), and evaluate its suitability for biopharmaceutical applications.
Result: Through a TFR competition binding affinity assay with HeLa human cervic carcinoma cells (CCL-2) and
Caco-2 human colon carcinoma cells (HTB-37), we show that rhTF competes similarly as hTF to bind TFR, and both
the TFR binding capacity and dissociation constant of rhTF are comparable to that of hTF. The endocytosis assay
confirms that rhTF behaves similarly as hTF in the slow accumulation in enterocyte-like Caco-2 cells and the rapid
recycling pathway in HeLa cells. The pulse-chase assay of rhTF in Caco-2 and HeLa cells further illustrates that
rice-derived rhTF possesses the similar endocytosis and intracellular processing compared to hTF. The cell culture
assays show that rhTF is functionally similar to hTF in the delivery of iron to two diverse mammalian cell lines,
HL-60 human promyelocytic leukemia cells (CCL-240) and murine hybridoma cells derived from a Sp2/0-Ag14
myeloma fusion partner (HB-72), for supporting their proliferation, differentiation, and physiological function of
antibody production.
Conclusion: The functional similarity between rice derived rhTF and native hTF in their cellular iron delivery, TFR
binding, and TFR-mediated endocytosis and intracellular processing support that rice-derived rhTF can be used as a
safe and animal-free alternative to serum hTF for bioprocessing and biopharmaceutical applications.
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Figure 1 TFR-competition binding assay of rhTF and hTF in
Caco-2 cells. Different concentrations of rhTF or hTF mixed with
1 μg/ml of 125I-hTF were added to confluent Caco-2 cells and
incubated at 4°C for 1 hr. Cells were then washed with cold PBS,
solubilized with 1 N NaOH, and the amount of radiolabelled hTF in
cell lysate was determined. The total cellular protein in the cell
lysate was measured, and used to normalize the data to ng of hTF
per mg cell protein (“ng/mg cell protein”). Data is represented as
average with error bars indicating standard deviation, n = 3.
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Iron is an essential element for cell growth and metabol-
ism. The major vehicle for iron delivery is serum transfer-
rin (TF), which plays a crucial role in tightly regulating
cellular iron uptake, transport, and utilization in nearly all
eukaryotes. The mechanism by which TF overcomes the
dual challenges of iron deficiency and overload in cells is
via a TF/TF receptor (TFR)-mediated endocytotic process
[1]. When TF is free of iron (apo-TF), it can bind two iron
molecules (diferric TF or holo-TF) at the extracellular pH
of 7.4. The resultant holo-TF binds to TFR with a greater
affinity than apo-TF, where two diferric TF molecules will
bind to the homodimeric TFR on the cell surface [2]. This
TF–TFR complex is then endocytosed into the early endo-
some, where the acidic environment (pH 5.5) triggers the
conformational change of TF–TFR complex and the sub-
sequent release of iron from TF. Finally, the TF–TFR com-
plex is recycled to the cell surface, where the lower affinity
of apo-TF for TFR at the neutral extracellular pH will dis-
sociate the complex and release the TF for re-use [3].
TF has been successfully used or being evaluated in a
wide range of important biopharmaceutical applications.
TF has been widely used as an important supplement in
culture medium for various mammalian cells and stem
cells because of the absolute requirement of iron for cel-
lular growth and proliferation [4,5]. TF has also been ac-
tively pursued as a drug delivery vehicle due to its
unique receptor-mediated endocytosis pathway as well
as its added advantages of being biodegradable, non-
toxic, and nonimmunogenic [6-9]. Moreover, TF is also
exploited for oral delivery of protein-based therapeutics
[10,11], as TFR is abundantly expressed in human
gastrointestinal (GI) epithelium and TF is resistant to
proteolytic degradation [10,12].
With the increasing concerns over the risk of trans-
mission of infectious pathogenic agents from the use of
human and animal plasma-derived TFs in both cell cul-
ture and drug delivery applications [13-15], rhTF has
long been pursued in a variety of expression systems
[16-24]. However, expression of fully functional TF has
been proven to be challenging largely due to hTF’s com-
plicated structural characteristics including 19 disulfide
bonds and two homologous lobes (N-lobe and C-lobe).
We have achieved a high level of expression yield of
rhTF in rice (Oryza sativa L.). Expression yield is 40% of
total soluble protein or 1% seed dry weight (10 g/kg)
[25]. The rice-derived rhTF is shown to be biochemically
and structurally similar to hTF and mammalian cell-
derived rhTF, and able to bind Fe3+ tightly yet reversibly
[15]. In the present work, we have characterized rice-
derived rhTF’s TFR-binding, TFR-mediated endocytosis
and intracellular processing, and its cellular iron delivery
to diverse mammalian cells through various cell-based
assays.Results
Comparison of TFR-binding affinity of rhTF and hTF
We compared the binding affinity of rhTF and hTF to
the TFR by a competition binding affinity assay. A series
of increasing concentrations of rhTF or hTF were mixed
with a fixed concentration (1 μg/ml) of 125I-labeled hTF,
and added to confluent Caco-2 cells for competition
binding to TFR (Figure 1). The binding of 125I-hTF in
Caco-2 cells is apparently inhibited with the addition of
one-fold excess or more of unlabeled rhTF or hTF, indi-
cating that both rhTF and hTF compete with 125I-hTF to
bind to TFR. Moreover, rhTF and hTF show the same
extent of dose-dependent inhibition of the binding of
125I-hTF to TFR in Caco-2 cells. This result indicates
that rhTF competes similarly as hTF to the TFR binding.
To directly compare rhTF’s TFR binding affinity with
that of hTF, the TFR binding capacity (Bmax) and equilib-
rium dissociation constant (Kd) values of both rhTF and
hTF were determined using saturation radioligand bind-
ing assays in HeLa cells (Figure 2, Table 1). Both rhTF and
hTF’s TFR binding in HeLa cells exhibits a similar dose-
dependent TFR binding profile (Figure 2). While the Kd
values of rhTF and hTF are significantly different (Table 1),
they are within the normal range for hTF (Kd = 2 – 8 nM)
[26-28]. The difference of Bmax values of hTF and rhTF
appears small but statistically significant (Table 1). It is
unknown if these Bmax values also fall into a normal range
because the Bmax value is cell line dependent and there is
no published Bmax values for hTF in HeLa cells. Neverthe-
less, these results demonstrate that both the TFR binding
capacity and dissociation constant of rhTF are compar-



























Figure 2 TFR-binding affinity of rhTF and hTF in HeLa cells.
Different concentrations of 125I-labeled hTF or rhTF were added to
confluent HeLa cells and incubated at 4°C for 2 hr. Cells were then
washed with cold PBS, solubilized with 1 N NaOH, and the amount
of radiolabelled hTF or rhTF in cell lysate was determined. The total
cellular protein in the cell lysate was measured, and used to
normalize the data to ng of hTF per mg cell protein (“ng/mg cell
protein”). Data is represented as average with error bars indicating
standard deviation, n = 3.
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Comparison of rhTF endocytosis in Caco-2 and HeLa cells
We have previously reported that the amount of endocy-
tosed hTF increases slowly and is accumulated linearly
in enterocyte-like Caco-2 cells, but reaches a plateau
rapidly in most other cell lines including HeLa cells due
to the rapid recycling and release [29]. To investigate if
rhTF’s endocytosis is similar to that of hTF, the endo-
cytosis kinetics of rhTF and hTF were assayed in HeLa
and Caco-2 cells. It shows that the internalization of
both hTF and rhTF increases rapidly and reaches a plat-
eau after just 1 hr in HeLa cells (Figure 3A), while
increases slowly and linearly up to the maximum 4 hr of
our testing time in Caco-2 cells (Figure 3B). Further-
more, both the total uptake and the time-course kinetics
of hTF and rhTF are similar regardless of the tested cell
line (Figure 3). These results demonstrate that rhTF
behaves similarly as hTF in the accumulation in Caco-2
cells and the rapid recycling pathway in HeLa cells.
Pulse-chase assay of rhTF in Caco-2 and HeLa cells
We then carried out pulse-chase assays to further evalu-
ate the endocytosis and intracellular processing of the
rhTF protein in Caco-2 and HeLa cells. Following an 1Table 1 TFR binding parameters of TF proteins in HeLa
cells
TFR binding parameters hTF rhTF P-Value
Bmax (pmol/mg cell protein)
1 6.78 ± 0.21 5.62 ± 0.20 0.0023b
Kd (nM)
2 4.42 ± 0.58 2.61 ± 0.46 0.0133a
1Bmax = maximum number of binding sites.
2Kd = equilibrium dissociate constant.
aP-value < 0.05.
bP-value < 0.01.or 3 hr chase period, the majority of rhTF is still asso-
ciated with the Caco-2 cells either intracellularly or sur-
face bound (Figure 4A), whereas the majority of rhTF is
released in HeLa cells and only about 11% of rhTF re-
main cell associated (Figure 4B). This result is consistent
with the above finding via the rhTF endocytosis kinetics
that rhTF is recycled rapidly in HeLa cells but accumu-
lated intracellularly in Caco-2 cells.
To have a direct comparison of rhTF and hTF for
their endocytosis and intracellular processing, pulse-
chase assays of rhTF and hTF were performed in
Caco-2 cells. After Caco-2 cells were pulsed with the
125I-labeled rhTF or hTF for 1 hr followed by being
chased with excess amount of unlabeled rhTF or hTF
for 1 or 3 hr, the amount of cell-associated and
released 125I-rhTF or hTF were determined to track
the movements of TF in Caco-2 cells (Figure 5). After
a 1 hr chase, the amount of 125I-rhTF or hTF protein
remaining inside the cells is about the same as the
amount associated with the cell surface (~35%)
(Figure 5A). Of the ~30% of the 125I-rhTF or hTF that
was released into the chase media, the majority
was released intact (Figure 5B). After a longer chase
period of 3 hr, both the intracellular and surface bound
125I-rhTF and hTF decreased to ~30% (Figure 5A), and
the decrease corresponded with a proportional in
crease in the amount released into the chase media
(Figure 5B). It shows that both the recycling and intra-
cellular accumulation of rhTF in Caco-2 cells is similar
to that of hTF. These results, taken all together, indi-
cate that the retention and recycling of rhTF in Caco-2
and HeLa cells is similar to that of hTF.
Cellular iron delivery ability of rhTF to support cell
proliferation and antibody production in mammalian cells
Iron is absolutely required to sustain mammalian cell
growth and proliferation and is essential for such pro-
cesses as electron transfer, oxygen transport, and DNA
synthesis [30,31]. We used two diverse cell lines (HL-60
and Sp2/0 hybridoma) to determine whether rhTF has
similar biological activity as serum hTF to support cell
growth and function. Furthermore, we measured the
production of antibody from hybridoma cells as an indi-
cation of normal cellular function.
HL-60 cells have been reported to have an absolute re-
quirement of transferrin and insulin for cell proliferation
[32], and have been widely used as a model system for
the study of myeloid differentiation, hematopoiesis, and
acute promyelocytic leukemia [33-35]. A dose response
comparison was performed with varying concentrations
of both hTF and rhTF to support the growth of HL-60
cells in a serum-free culture system. As shown in
Figure 6, partially iron saturated rhTF and human holo-



















































Figure 3 Comparison of uptake kinetics of rhTF and hTF in HeLa and Caco-2 cells. A. Uptake kinetics of rhTF and hTF in HeLa cells. One
μg/ml of 125I-labeled rhTF was added to confluent HeLa cells, and incubated at 37°C for 0.5, 1, 2, and 4 hr. In a comparison assay, 1 μg/ml of
125I-hTF was added to confluent HeLa cells, and incubated at 37°C for 0.5 and 3 hr. Cells were then washed with cold PBS, solubilized with 1 N
NaOH, and radioactivity in cell lysate was determined. B. Uptake kinetics of rhTF and hTF in Caco-2 cells. One μg/ml of 125I-labeled hTF or rhTF
was added to confluent Caco-2 cells and incubated at 37°C for 0.5, 1, 2, and 4 hr. Cells were then washed with cold PBS, solubilized with 1 N
NaOH, and radioactivity in cell lysate was determined. The total cellular protein in the cell lysate was measured, and used to normalize the data
to ng of hTF per mg cell protein (“ng/mg cell protein”). Data is represented as average with error bars indicating standard deviation, n = 3.
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that rhTF has similar potency to hTF and can deliver ne-
cessary iron to HL-60 cells similarly as hTF.
To investigate rhTF’s effectiveness of delivering iron to
Sp2/0 hybridoma cells to stimulate cell proliferation and
antibody production, we assayed three forms of rhTF or
hTF, each at different degrees of iron saturation, i.e.,
iron-free (apo), partially iron saturated, iron-saturated
(holo). We first compared the growth kinetics of hybri-
doma cells in serum-free medium supplemented with the
3 forms of hTF or rhTF at 5 mg/L over 6 days of culture
(Figure 7). It shows that cells proliferated at a greatly
reduced rate through the initial 2 days and failed to pro-
liferate beyond two days of culture in medium withoutFigure 4 Pulse Chase Assay of rhTF in Caco-2 and HeLa Cells. Conflue
medium containing 3 μg/ml 125I-labelled hTF or rhTF at 37°C. Then, the puls
medium followed by washing cell monolayers with cold DMEM medium su
by incubation with excess molar (0.3 mg/ml) of unlabeled hTF or rhTF in ch
associated (A) and released (B) hTF or rhTF was determined. Data is represeTF (Figure 7, Yellow), suggesting that the little amount of
serum-derived transferrin in the cells is not sufficient to
support a robust growth. However, robust growth of cells
was enabled upon the addition of transferrin to serum-
free medium. Hybridoma cells grew in log-phase through
day 3, reached stationary phase on day 3–4, and entered
death phase on day 5–6 (Figure 7). Furthermore, cells
grown in medium supplemented with each of the 3 forms
of rhTF showed similar growth kinetics as cells grown in
medium supplemented with the 3 forms of hTF. Thus,
rhTF and hTF resulted in similar, robust, growth kinetics
regardless of their respective degree of iron saturation.
We then performed a dose response study to compare
the activity of the hTF and rhTF using three cell culturent Caco-2 or HeLa cells were pulsed for 1 hr by incubation with pulse
e medium with radiolabeled TF was removed by aspiration of the
pplemented with 0.1% BSA. Caco-2 and HeLa cells were then chased
ase medium at 37°C. After chasing for 1 or 3 hr, the percentage of cell-
nted as average with error bars indicating standard deviation, n = 3.
Figure 5 Pulse Chase Assay comparing hTF and rhTF in Caco-2 cells. Confluent Caco-2 cells were pulsed for 1 hr by incubation with pulse
medium containing 3 μg/ml 125I-labelled hTF or rhTF at 37°C. Then, the pulse medium with radiolabeled TF was removed by aspiration of
medium followed by washing cell monolayers with cold DMEM medium supplemented with 0.1% BSA. Caco-2 cells were then chased by
incubation with excess molar (300 μg/ml) of unlabeled hTF or rhTF in chase medium at 37°C. After chasing for 1 or 3 hr, the percentage of
cell-associated (A) and released (B) hTF or rhTF were determined. Data is represented as average with error bars indicating standard
deviation, n = 3.
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after 3 days of culture, 2.) sustained cell growth as mea-
sured by cumulative cell density through 6 days of cul-
ture, and 3.) antibody productivity at the end-of-batch
culture on day 6.
Figure 8A shows the dose response comparison of the
transferrins to support log-phase cell proliferation. We
found that rhTF and hTF exhibit the same dose response
curve to support cell proliferation regardless of their re-
spective degree of iron saturation.
Furthermore, we compared rhTF to hTF using the par-
ameter of 6-day cumulative cell density (CCD), also
known as IVC-integral of the viable cell concentration.




















Figure 6 Effect of rhTF on the proliferation of HL-60 cells. The
viable cell concentration of HL-60 cells after three days culture in
serum-free medium supplemented with no hTF, 0.005, 0.05, 0.5,
5 and 50 mg/L of hTF (holo-form, from Sigma) or rhTF (Partial;
partially iron saturated) was determined by fluorescence assay. Data
is represented as average with error bars indicating standard
deviation, n = 3.that measures the ability of a cell culture medium to
support sustained high density cell growth [36] through-
out an entire batch process. As shown in Figure 8B,
rhTF and hTF have the similar CCD values at their
equivalent concentrations. However, the generation of
CCD was independent of the iron saturation status of
both rhTF and hTF.
The concentration of monoclonal antibody produced
by Sp2/0 cells grown in medium supplemented with a
range of concentrations of rhTF or hTF at different
degrees of iron saturation was compared (Figure 8C).
rhTF and hTF stimulated the production of a similar
amount of antibody at their equivalent concentration,
and the production of antibody increased to the same
extent with the increment dose for all of the transferrinsFigure 7 The growth kinetics of hybridoma cells in serum-free
medium supplemented with hTF or rhTF at 5 mg/L. The hTF and
rhTF were compared at different degrees of iron saturation at
5 mg/L concentration. Apo, iron-free; Partial, partially iron saturated;
Holo, iron saturated. Error bars denote the standard deviation of
triplicate cultures.
Figure 8 Comparison of rhTF and hTF for supporting
hybridoma cell proliferation, cumulative cell density, and
antibody production. Sp2/0 hybridoma cells were cultured in serum-
free medium supplemented with hTF or rhTF at 0.03, 0.1, 0.3, 1, 5, or 30
mg/L. The hTF and rhTF were compared at different degrees of iron
saturation: Apo, iron-free; Partial, partially iron saturated; Holo, iron
saturated. A. Comparison of hTF to rhTF for cell proliferation during log
phase growth (day0 through day3). B. Comparison of hTF to rhTF for
cumulative cell density. Cumulative cell density is the estimated area
under the growth curve and is indicative of the total cell mass
generated by a culture system. Units are given in cell-days/ml. C.
Comparison of hTF to rhTF for antibody production. Error bars denote
the standard deviation of triplicate cultures.
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hTF for the delivery iron to hybridoma cells as evidenced
by enhanced cell proliferation and the support of the
cell’s physiological function of antibody production.Discussion
The essential function of TF is to transport and deliver
irons to cells through the unique TF-TFR complex-
mediated endocytosis pathway [1,3]. Our previous cell-
free biochemical and biophysical studies show that both
lobes of rhTF bind Fe3+ tightly yet reversibly similarly to
hTF [15,25]. In this study we further characterize the
TFR binding, TFR-mediated endocytosis and iron deliv-
ery function of rhTF using cell-based assays.
Our data show that the TFR-mediated endocytosis and
intracellular processing of rhTF, as evaluated by total cell
uptake, kinetics, and pulse-chase assays, is similar to that
of hTF. This result is consistent with our previous find-
ing in a competitive immunoassay that rhTF is equiva-
lent to baby hamster kidney (BHK) cell derived
recombinant N-His hTF in its ability to bind to the sol-
uble portion of the TFR [15]. It is also in good agree-
ment with other reports that hTF’s internalization
increases linearly with time in enterocyte-like Caco-2
cells due to this type of cells’ unique accumulation of TF
[29]. These results indicate that rhTF is similar to hTF in
its ability of binding to human TFR, and then being
endocytosed through TFR-mediated pathway. While the
in vitro cell-based assays demonstrate the similarity of
cellular iron delivery processing of rhTF and hTF, we
have carried out a preliminary in vivo study to compare
the serum half-life of rice-derived rhTF with that of hTF
and the yeast-derived aglycosylated rhTF (CellPrimeTM
rTransferrin AF, Millipore). The elimination half-lives
(i.e. β-phase) of rice-derived rhTF, yeast-derived aglyco-
sylated rhTF and hTF are 14.8, 13.8, and 18.6 hr, respect-
ively (Unpublished data). The relatively shorter serum
half-life could be due to the lack of N-linked glycans in
the two recombinant transferrins [14,15,25]. Neverthe-
less, rice-derived rhTF is shown to have a sufficiently
long serum half-life compared to native hTF. These
results support that rhTF can be used as an animal-free
alternative to serum hTF for pharmaceutical applications
as a carrier to a number of drug molecules for drug tar-
geting and delivery [6-8,37].
We also use cell culture assay to assess the functional
equivalency of rhTF to hTF. We demonstrate that rice-
derived rhTF is equivalent to hTF to carry out cellular
iron delivery for supporting cell growth and differenti-
ation of HL-60 cells, which have been described as
dependent on TF to support cell proliferation [32]. Simi-
larly, we show that rhTF and hTF has the same ability to
deliver iron to support the cell growth and antibody
production of Sp2/0 hybridoma cells, which are widely
used for production of therapeutic antibodies [38]. In
addition, a study by D-Finitive Cell Technologies also
indicates rhTF has equal activity to hTF and iron chelate
to improve the expansion of both mononuclear cells and
CD34+ stem cells (Paul Price, unpublished data). All
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able to deliver irons to various mammalian cells for sup-
porting cell physiological function.
Our data show that the iron saturation status of rhTF
or hTF has little impact on the stimulation of cell prolif-
eration and antibody production in the HL-60 and mur-
ine hybridoma cells. Although apo-TF has no bound
iron to deliver to cells and has low affinity for TFR [3],
its equivalent stimulation effect on cell proliferation and
antibody production as holo-TF is most likely due to the
availability of iron in culture medium and the binding of
iron by apo-TF. Iron is an ingredient in many classical
formulations including MEM, DMEM, alpha MEM,
M199, and DMEM/F12, and thus apo-TF is likely be-
coming saturated with iron from the medium.
Conclusion
Rice-derived rhTF is shown to be similar to hTF in its
TFR binding, TFR-mediated endocytosis and cellular iron
delivery function. This functional similarity, together
with our previous reports showing the structural and bio-
chemical similarities, makes rice-derived rhTF a low-cost
and animal-free alternative to plasma-derived hTF for
bioprocessing and biopharmaceutical applications. Cur-
rently, cell culture grade rhTF (OptiferrinTM) is available
for use in cell culture applications. A more highly puri-
fied biopharmaceutical grade of rhTF is also being devel-
oped at Ventria Bioscience for use in pharmaceutical
applications such as being used as a potential conjugate
carrier to a number of drug molecules, including various
chemotherapy drugs for drug targeting and delivery.
Methods
Materials
Recombinant hTF was expressed and purified from trans-
genic rice grains as described previously [25]. The native
hTF, ferric ammonium citrate, bovine serum albumin
(BSA), 40-hydroxyazobenzene-2-carboxylic acid (HABA)/
Avidin reagent, and horseradish peroxidase (HRP)-conju-
gated anti-goat IgG antibody, sodium selenite, and etha-
nolamine were obtained from Sigma (St. Louis, MO). Cell
culture Dulbecco’s modified Eagle’s medium (DMEM)
and Fetal bovine serum (FBS) were products of Mediatech
(Manassas, VA). Dulbecco’s modified Eagle’s medium-
Ham F-12 nutrient mixture (DMEM/F12) was purchased
from Life Technologies. Trypsin-EDTA was purchased
from Gibco BRL (Rockville, MD). The Na-125I was from
Perkin Elmer (Waltham, MA). The BCA (bicinchoninic
acid) protein assay kit, Sulfo-NHS-LC-Biotin, and PBS
reagents (NaCl, KCl, Na2HPO4, KH2PO4) was from
Thermo-Fisher (Waltham, MA). The culture dishes were
products of Corning (Corning, NY). Avidin-coated plates
were products of Roche. TMB (3,30,5,50-Tetramethylben-
zidine) Microwell Peroxidase Substrate System was theproduct of KPL (Gaithersburg, MD). Cellastim™ rhAlbu-
min is a product of InVitria (Fort Collins, CO). All other
chemicals that are not specified above were purchased
from Sigma.
HeLa human cervic carcinoma cells (CCL-2), Caco-2
human colon carcinoma cells (HTB-37), HL-60 human
promyelocytic leukemia cells (CCL-240) and murinehy-
bridoma cells, derived from a Sp2/0-Ag14 myeloma fu-
sion partner (HB-72) were obtained from American Type
Culture Collection (Rockville, MD, USA). All cell lines
were maintained in DMEM/F12 medium supplemented
with 10% FBS. Prior to assay, cells were washed three
times with serum-free DMEM/F12 medium without TF.
Preparation of radiolabeled hTF and rhTF
Prior to radiolabeling, both rhTF and hTF were first
saturated with iron by incubating 10 mg protein with 10
mg ferric ammonium citrate at 37°C in 2 mL of PBS, pH
7.2, for 2 hr followed by dialyzing against 2 L of PBS
overnight at 4°C. Then, the iron-saturated TF was iodi-
nated using the chloramines-T method [39]. The specific
activities of 125I-TF ranged from 400 to 900 cpm/ng.
TFR-binding affinity of rhTF
The TFR-binding affinity of rhTF was assessed using
Caco-2 and HeLa cells. The Caco-2 and HeLa cells were
adapted to growth as reported by Grasset et al. [40] and
Zaro et al. [41], respectively, and then were seeded in a
12-well cluster plate to obtain confluent cell monolayers
within a week after passage. Prior to TFR binding assay,
Caco-2 and HeLa cells were washed twice with serum-
free medium at room temperature and then pre-
incubated with serum-free medium with 1 mg/ ml BSA
at 37°C for 1 hr to deplete endogenous TF.
TFR-competition binding affinity assay in Caco-2 cells
One μg/ml 125I-hTF was mixed with 0.1, 0.3, 1, 3, 10 or
30 μg/ml unlabeled hTF or rhTF, respectively, and added
to confluent Caco-2 cells followed by incubation at 4°C
for 2 hr. The medium was then aspirated, and the cells
were washed with ice-cold PBS and then solublized in 1
M NaOH. The amount of 125I-hTF and the cell protein
content in the lysates were measured using a gamma
counter and the BCA assay kit (Pierce), respectively. The
non-specific surface binding of 125I-hTF was determined
in wells containing cells supplemented with a 100-fold
excess of unlabeled hTF or rhTF. The amount of
125I-hTF bound to TFR was calculated by subtracting
non-specific surface bound 125I-hTF from the total
amount of 125I-hTF in the lysates.
TFR-binding affinity assay in HeLa cells
Saturation radio-ligand binding assays were performed
in HeLa cells to determine the binding capacity (Bmax)
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rhTF. Increasing concentrations of 125I-hTF or rhTF (0.1,
0.3, 1, 3, or 10 μg/ml) were added to the confluent HeLa
cells followed by incubation at 4°C for 2 hr. In parallel,
cells incubated with a 100-fold excess of unlabeled hTF
or rhTF was used to normalize the background caused
by non-specific binding. Then, the TFR-binding affinity
was assessed by the same method as described above in
section TFR-competition binding affinity assay in Caco-
2 cells.
TFR-mediated endocytosis of rhTF
The TFR-mediated endocytosis of rhTF was assessed
using Caco-2 and HeLa cells, and the culture of these
two cells was the same as described above in TFR bind-
ing affinity assay.
Comparison of endocytosis of rhTF in HeLa and Caco-2 cells
One μg/ml 125I-rhTF was added to confluent HeLa or
Caco-2 cells followed by incubation at 37°C for 0.5, 1, 2,
or 4 hr. In parallel, a 100-fold excess of unlabeled hTF
was added to the wells containing 125I-rhTF to assay the
non-specific binding of the 125I-rhTF. The medium was
aspirated, and the cells were washed with ice-cold PBS
and solublized in 1 M NaOH. The radioactivity of the
lysates was counted using a gamma counter, and the cell
protein content was determined using the BCA assay to
determine the total cellular uptake of 125I-rhTF. TFR-
mediated cellular uptake of rhTF was calculated by sub-
tracting non-specific surface binding of rhTF from the
total cellular uptake of rhTF.
Comparison of endocytosis of rhTF and hTF in Caco-2 cells
To investigate if the cellular uptake of rhTF is same as
its native counterpart hTF, 1 μg/ml 125I-rhTF or hTF was
added to confluent Caco-2 cells followed by incubation
at 37°C for 0.5, 1, 2, or 4 hr. Then, the internalized
125I-rhTF or hTF in Caco-2 cells was assayed with the
same method as described above for comparison of
endocytosis of rhTF in HeLa and Caco-2 cells.
Pulse-chase assays of rhTF in HeLa and Caco-2 cells
Confluent HeLa and Caco-2 cells were first incubated
with pulse medium containing 3 μg/ml 125I-rhTF at 37°C
for 1 hr. In parallel, non-specific binding of 125I-rhTF
was determined in wells containing 125I-rhTF and a 100-
fold excess of unlabeled hTF. The unbound 125I-rhTF
was then removed by three washes with serum-free
medium. The pulse medium was aspirated, and the cell
monolayers were washed with cold DMEM medium
supplemented with 0.1% BSA to remove residual pulse
medium. Chase medium, which contains 0.3 mg/ml un-
labeled hTF to prevent re-internalization of 125I-rhTF,
was then added to cells followed by incubation at 37°Cfor 1 or 3 hr. To determine the percentage of intact
recycled 125I-rhTF in the chase medium, the collected
medium was treated with 15% trichloroacetic acid for 15
min at 4°C. The medium samples were centrifuged, and
the radioactivity in the pellet (intact) and supernatant
(degraded) was determined. Meanwhile, the cell mono-
layers were incubated with trypsin, which detaches the
cells and removes surface bound TF, and centrifuged to
separate the surface bound (supernatant) and intracellu-
lar (pellet) 125I-rhTF. The data were presented as a per-
centage of initially endocytosed ligands (sum of release,
surface-bound, and intracellular retention).Pulse-chase assays of rhTF and hTF in Caco-2 cells
Confluent Caco-2 cells were first incubated with pulse
medium containing 3 μg/ml 125I-hTF or rhTF at 37°C for
1 hr. Then, the endocytosis processing of radiolabeled
rhTF and hTF in Caco-2 cells were assayed with the
same method as described above in pulse-chase assays
of rhTF in HeLa and Caco-2 cells.The cellular iron delivery ability of rhTF to support cell
growth and antibody production in mammalian cells
Cell proliferation assay using human promyelocytic
leukemia HL-60 cells was performed in DMEM/F12
medium supplemented with recombinant human insulin
as described [32], and with either hTF or rhTF at 0.005,
0.05, 0.5, 5, or 50 mg/L. Cells were washed in DMEM/
F12 medium and seeded at 5,000 viable cells per well in
a 96 well plate with triplicate wells per condition. Fol-
lowing a 3 day incubation, the relative viable cell count
was determined by Resazurin (alamarBlueW) fluores-
cence assay [42] and reported as fluorescence units (FU)
Cell growth and antibody production of Sp2/0 hybri-
doma cells were assessed in a serum-free medium com-
posed of DMEM/F12 medium supplemented with 10
mg/L recombinant human insulin, 0.0067 mg/L sodium
selenite, 2 mg/L ethanolamine, 1 g/L Cellastim™ rhAlbu-
min from InVitria (Fort Collins, CO). A series of in-
creasing concentrations of rhTF or hTF at 0.1, 0.3, 1, 3,
10, or 30 mg/L were used for the comparison of rhTF to
hTF. Washed hybridoma cells were seeded in a 6 well
plate at 0.5 x 105 viable cells/ml in triplicate 4 ml cul-
tures. Cells were maintained in a humidified incubator
at 37°C with 6% CO2. The concentration of viable cells
was determined daily for 6 days by flow cytometer
(Guava, Millipore) until end of batch culture was
obtained (cell viability of 50% or less). The concentration
of IgG1 monoclonal antibody secreted into the medium
after 6 days of culture was determined by a fluorescence-
based ELISA developed by InVitria using phycoerythrin
conjugated detector antibody (Jackson ImmunoResearch,
W. Grove, PA).
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